KBRA Assigns Preliminary Ratings to MSC 2022-L8
NEW YORK–(BUSINESS WIRE)–#KBRA–KBRA is pleased to announce the assignment of preliminary ratings to 38 classes…
NEW YORK–(BUSINESS WIRE)–#KBRA–KBRA is pleased to announce the assignment of preliminary ratings to 38 classes…
~US$254 million raised in public listing via completion of business combination with Bridgetown 2 with…
Awarded the top project in the “A.I. For Good” category for their work in rural…
Macellum originally nominated a control slate while owning just 1,000 shares in December and prior…
NEW YORK–(BUSINESS WIRE)–Signature Bank (Nasdaq:SBNY), a New York-based, full-service commercial bank, announced today the Bank’s…
Appointment Will Accelerate Introduction of Spintly Thread-based Wireless Access Control Solutions SAN JOSE, Calif.–(BUSINESS WIRE)–#Buildingaccesscontrol—Spintly,…
Only 4 out of 10 organizations believe they are highly effective at delivering the kind…
Snyk Chief Architect Josh Stella Explains Why Attackers Aren’t Targeting Cloud Environments With Ransomware and…
Precision medicine initiative leverages innovative technologies and unprecedented 80% diverse participant base to drive new…
SP-102 (SEMDEXA™), with 401 patients enrolled in the C.L.E.A.R. trial (Corticosteroid Lumbosacral Epidural Analgesia in…
IRVINE, Calif., March 18, 2022 (GLOBE NEWSWIRE) — Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced…
CARLSBAD, Calif., March 18, 2022 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the…
– 5th Annual Neuroscience Innovation Forum – – BIO-Europe Spring® 2022 – CUPERTINO, Calif., March…
SYDNEY, AUSTRALIA, March 18, 2022 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep”…
SYDNEY, AUSTRALIA, March 18, 2022 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep”…
Sanofi moves forward with EUROAPI listing on Euronext Paris Sanofi will give its shareholders…
WALTHAM, Mass., March 18, 2022 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a life sciences company…
PITTSBURGH, March 18, 2022 (GLOBE NEWSWIRE) — Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader…
– Topline data from the eblasakimab Phase 1b multiple-ascending-dose study will be presented during the…
– Key anticipated catalysts in 2022 include submission of IND and/or CTA for DB-OTO and…